N@N

Tiago Fauth Maintained (BMRN) at Buy with Increased Target to $127 on, Feb 28th, 2023

^{Published on 2024-10-28 01:57:49 - WOPRAI, Tiago Fauth}
 

Tiago Fauth of Credit Suisse, Maintained "BioMarin Pharmaceutical Inc." (BMRN) at Buy with Increased Target from $110 to $127 on, Feb 28th, 2023.

Tiago has made no other calls on BMRN in the last 4 months.

There are 5 other peers that have a rating on BMRN. Out of the 5 peers that are also analyzing BMRN, 3 agree with Tiago's Rating of Hold. Following are those relevant analyst calls for the last 4 months

---

• Leland Gershell of "Oppenheimer" Downgraded from Buy to Hold on, Wednesday, February 22nd, 2023
• David Lebowitz of "Citigroup" Initiated at Hold and Held Target at $116 on, Tuesday, February 21st, 2023
• Kostas Biliouris of "BMO Capital" Initiated at Hold and Held Target at $107 on, Monday, January 30th, 2023

These are the ratings of the 2 analyists that currently disagree with Tiago

---

• Joseph Schwartz of "SVB Leerink" Maintained at Buy with Increased Target to $130 on, Friday, February 3rd, 2023
• Akash Tewari of "Jefferies" Maintained at Strong Buy with Increased Target to $120 on, Tuesday, November 29th, 2022

Contributing Sources

---